Navigation Links
ViroPharma To Acquire Lev Pharmaceuticals
Date:7/15/2008

Additionally, ViroPharma agreed to make a $20 million investment in Lev, at signing, by purchasing 9,661,836 shares of Lev common stock at a 10 percent premium to the five day average closing price of Lev's shares for the period ending Friday, July 11, 2008, sold pursuant to Lev's effective registration statement on Form S-3.

J.P. Morgan Securities Inc. advised ViroPharma and DLA Piper acted as legal counsel. In addition, Piper Jaffray & Co. provided a fairness opinion to ViroPharma's board of directors. J.P. Morgan Securities Inc., as successor to Bear, Stearns & Co. Inc., advised Lev and provided a fairness opinion to Lev's board of directors. Willkie Farr & Gallagher LLP and Becker & Poliakoff, LLP acted as legal counsel to Lev.

Conference Call and Webcast Information

ViroPharma will host a live teleconference and webcast (featuring slide presentation) with senior management to discuss the strategic acquisition of Lev Pharmaceuticals on Tuesday, July 15, 2008 at 10:30 a.m. ET. Members of Lev Pharmaceuticals senior management will be available during the question and answer period. To participate in the conference call, please dial 888-299-4099 (domestic) and 302-709-8337 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

Alternatively, the live webcast of the conference call and slide presentation can be accessed via ViroPharma's website at http://www.viropharma.com. Windows Media or Real Player will be needed to access the webcast. An audio archive will be available at the same address until August 1, 2008.

Cinryze(TM) Regulatory Status

On May 2, 2008, the Blood Products Advisory Committee (BPAC) to the U.S. Food and Drug Administration (FDA) voted unanimously that there is sufficient evidence of the safety and efficacy for the approval of Cinryze for the prophylactic treatment of HAE. Th
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Due to a misstatement ... week, the Adult Stem Cell Technology Center, LLC ( ASCTC ... stem cell therapy research that might benefit ALS patients. ... for new stem cell technologies and therapeutic applications, FRC listed ... Bucket Challenge donors who wish not to support research ...
(Date:8/28/2014)... City, Ca. (PRWEB) August 28, 2014 ... E3 rating for an alcohol-based hand sanitizer, asks food ... harvest by comparing the hand sanitizer they’re currently using ... Spray . Hand hygiene is critical to fighting cross-contamination ... environment. Best Sanitizers believes there are key criteria ...
(Date:8/28/2014)... PA (PRWEB) August 28, 2014 The ... create a culture that will allow individuals to perform ... becoming increasingly important for employers looking to compete in ... industries are embracing this trend, as the sector increasingly ... of a company, which will have real results on ...
(Date:8/28/2014)... Florida State University research team has led to a ... white light, and convert photon energy directly to mechanical ... , Biwu Ma, associate professor in the Department of ... Engineering, created the molecule in a lab about a ... creation has many other unique capabilities. , For example, ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Novel 'butterfly' molecule could build new sensors, photoenergy conversion devices 2
... Exagen Diagnostics, Inc. , a specialty focused ... tests for rheumatologists and gastroenterologists, announced today the appointment ... Tornoe has more than 20 years of ... making him a key hire as Exagen broadens its ...
... LOS ANGELES, Aug. 10, 2011 Genesis Biopharma, ... cancer immunotherapies, today announced it has signed a ... National Cancer Institute (NCI).  Under the terms of ... Biopharma will work with Steven A. Rosenberg, M.D., ...
... DIEGO, Aug. 9, 2011 Verenium Corporation (Nasdaq: ... development and commercialization of high-performance enzymes, today reported a summary ... quarter and six months ended June 30, 2011. ... terms of product revenues and partnership negotiations in the first ...
Cached Biology Technology:Eric Tornoe Joins Exagen Diagnostics as President and COO 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 2Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 2Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 5Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 6Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 7Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 8Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 9
(Date:8/28/2014)... Yale University researchers have identified a handful of bacterial ... as Crohn,s disease and ulcerative colitis, using patients, own ... are published Aug. 28 in the journal Cell ... intestinal microbiota, which plays a critical role in the ... only a small number of bacterial species affect a ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program has ... of Human Genetics from October 18 22, 2014 ... to promote the entry of students, post doctorates and ... basic science community and to encourage the participation of ... This year MARC conferred 16 awards totaling $29,600., ...
(Date:8/28/2014)... The support of peer groups and clinicians ... programs, according to recent University of Georgia research. ... the Athens-Clarke County area determined that role models ... of mothers of infants. , "Mothers who received ... at breastfeeding," said study co-author Alex Anderson, an ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2Breastfeeding study shows need for effective peer counseling programs 2
... is available in German . , ... species of the Galapagos archipelago, treks slowly and untiringly ... Institute for Ornithology in Radolfzell, together with the Charles ... acceleration measurements to find out that especially the dominant ...
... A study published in the current issue ... available on-line at http://www.ingentaconnect.com/content/cog/ct/ , has found ... (SM-MSCs) or adipose tissue (ADSCs) were injected into ... laboratory rats that had suffered a myocardial infarction, ...
... more than 200 million people every year mainly in ... the Plasmodium parasite, which is spread by infected ... but more than half a million people nevertheless die every ... during the past decade have reduced the distribution of the ...
Cached Biology News:Galapagos tortoises are a migrating species 2Galapagos tortoises are a migrating species 3Study suggests different organ-derived stem cell injections improve heart function 2New method for diagnosing malaria 2
... performance for all vacuum requirements. A 3 ... to suit all applications. The large, sideview ... proper oil levels at a glance. The ... work with all Thermo Savant SpeedVac concentrating ...
... used to assess the effect of drugs on ... and rats using one unit in a safe ... are placed on textured drums to avoid slipping. ... platforms below, its test results are recorded. • ...
... 8-iso-13,14-dihydro-15-keto Prostaglandin F2α (8-iso-13,14-dihydro-15-keto PGF2α) ... 8-isoprostane (8-iso PGF2α), in rabbits, monkeys ... PG-like product of non-specific lipid peroxidation. ... infused 8-isoprostane is converted primarily to ...
... 3C protease from human rhinovirus (HRV 3C) ... brand line of restriction grade proteases. The ... 6XHis-fusion protein, which recognizes the same cleavage ... small, 22 KDa size of the protease, ...
Biology Products: